2574438-65-4
2574438-65-4
Chemical Structure
Belrestotug
Synonym(s): EOS-448; EOS884448; GSK4428859A
- CAS No.: 2574438-65-4
- Formula:N/A
- Molecular Weight:(145.7 kDa)
SMILES: [Belrestotug]
Biological Activity: Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Belrestotug | 97% | Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cuende J, et al. a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)[J]. medRxiv, 2025: 2025.07. 25.25332187.
- [2]. Cuende J, et al. Pharmacodynamic assessment of a-TIGIT mAb EOS-448 highlights multiple FcγR-mediated mode-of-actions in blood and tumor of patients with advanced solid tumors[J]. Cancer Res, 2022, 82(12_Suppl): LB189.
Keywords
